880 Prostate cancer cell proliferation is strongly reduced by combination treatment with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (‘Iressa’) and the anti -androgen bicalutamide (‘casodex’)

M.Bologna; A.Angelucci; C.Festuccia; G.L.Gravina; P.Muzi; C.Vicentini

首页> 外文期刊>European Journal of Cancer Supplements >880 Prostate cancer cell proliferation is strongly reduced by combination treatment with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (‘Iressa’) and the anti -androgen bicalutamide (‘casodex’)

【24h】

880 Prostate cancer cell proliferation is strongly reduced by combination treatment with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (‘Iressa’) and the anti -androgen bicalutamide (‘casodex’)

机译：与表皮生长因子受体酪氨酸激酶抑制剂ZD1839（'Iressa'）和抗雄激素比卡鲁胺（'casodex'）联合治疗可大大降低880前列腺癌细胞的增殖。

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2003年第5期|共1页
作者
M.Bologna; A.Angelucci; C.Festuccia; G.L.Gravina; P.Muzi; C.Vicentini;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. 880 Prostate cancer cell proliferation is strongly reduced by combination treatment with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (‘Iressa’) and the anti -androgen bicalutamide (‘casodex’) [J] . M.Bologna, A.Angelucci, C.Festuccia, European Journal of Cancer Supplements . 2003,第5期

机译：与表皮生长因子受体酪氨酸激酶抑制剂ZD1839（'Iressa'）和抗雄激素比卡鲁胺（'casodex'）联合治疗可大大降低880前列腺癌细胞的增殖。
2. Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro (Retraction of Vol 115, Pg 630, 2005) [J] . Festuccia C., Gravina G. L., Angelucci A., International Journal of Cancer =: Journal International du Cancer . 2019,第2期

机译：表皮生长因子受体酪氨酸激酶抑制剂，吉非替尼（Iressa）和非甾体类抗衰老原，Bicaletamide（Casodex），在前列腺癌细胞中，在前列腺癌细胞中的添加剂抗肿瘤效应（卷115，PG 630,2005的收缩）
3. Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures. [J] . Vicentini C, Festuccia C, Gravina GL, Journal of Cancer Research and Clinical Oncology . 2003,第3期

机译：前列腺癌细胞的增殖在体外在人细胞系和原代培养物中被表皮生长因子受体酪氨酸激酶抑制剂ZD1839大大降低。
4. The Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 (Iressa) Suppresses Proliferation and Invasion of Human Oral Squamous Carcinoma Cells via p53 Independent and MMP, uPAR Dependent Mechanism [C] . EUN JU LEE, JIN HA WHANG, NAM KYEONG JEON, Meeting on Cell Signaling World: Signal Transduction Pathways as Therapeutic Targets . 2007

机译：表皮生长因子受体酪氨酸激酶抑制剂ZD1839（Iressa）通过独立于p53和MMP，uPAR依赖性机制抑制人口腔鳞状细胞癌细胞的增殖和侵袭
5. Unanticipated Effects of Tyrosine Kinase Inhibitors on Vitamin D Receptor Expression and Gene Regulation In Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer. [D] . Timberlake, Alexandra F. 2017

机译：酪氨酸激酶抑制剂对表皮生长因子受体突变的非小细胞肺癌中维生素D受体表达和基因调控的意外影响。
6. Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa ZD1839) and the antioestrogen fulvestrant (Faslodex ICI 182780) in breast cancer cells [O] . S Okubo, J Kurebayashi, T Otsuki, 2004

机译：表皮生长因子受体酪氨酸激酶抑制剂吉非替尼（IressaZD1839）和抗雌激素治疗剂（FaslodexICI 182780）在乳腺癌细胞中的累加抗肿瘤作用
7. Retraction: Festuccia, C., Gravina, G. L., Angelucci, A., Millimaggi, D., Muzi, P., Vicentini, C. and Bologna, M. (2005), Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro. Int. J. Cancer, 115: 630–640. https://doi.org/10.1002/ijc.20917. [O] . 2019

机译：收缩：Festccia，C.，Gravina，GL，Angelucci，A.，Millimaggi，D.，Muzi，P.，Vicentini，C.和Bologna，M。（2005），表皮生长因子受体酪氨酸激酶的添加剂抗肿瘤效应在体外，抑制剂，吉非替尼（Iressa）和非甾体抗原，Bicalid酰胺（Casodex），在前列腺癌细胞中。 int。 J.癌症，115：630-640。 https://doi.org/10.1002/ijc.20917。

880 Prostate cancer cell proliferation is strongly reduced by combination treatment with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (‘Iressa’) and the anti -androgen bicalutamide (‘casodex’)

著录项

相似文献

相关主题

期刊订阅